Advertisement
Advertisement

Archive

Dose-dependent thrombus resolution due to oral plasminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH07-11-0669
Issue: 2008: 99/4 (Apr) pp. 647-797
Pages: 749-758

Dose-dependent thrombus resolution due to oral plasminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis

Sanjiv Baxi 1, David L. Crandall 3, Thomas R. Meier*,1,2, Shirley Wrobleski 1, Angela Hawley 1, Diana Farris 1, Hassan Elokdah4†, Robert Sigler 5, Robert G. Schaub**, 3, Thomas Wakefield 1, Daniel Myers 1, 2
1 Jobst Vascular Research Laboratories, Section of Vascular Surgery, University of Michigan Medical Center, Ann Arbor, Michigan, USA; 2 Unit for Laboratory Animal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA; 3 Cardiovascular and Metabolic Diseases Research, Wyeth Research, Cambridge, Massachussetts, USA; 4 Chemical & Screening Sciences Research, Wyeth Research, Collegeville, Pennsylvania, USA; 5 Walker Downey & Associates, Inc., Verona, Wisconsin, USA

Keywords

Stenosis, Plasminogen activator inhibitors, Deep vein thrombosis, Venous thrombosis, Animal models

Summary

This study aimed to evaluate a small-molecule PAI-1 inhibitor (PAI-039; tiplaxtinin) in a rodent stenosis model of venous thrombosis in a two-phase experiment. Phase 1 determined the efficacy of tiplaxtinin against Lovenox (LOV), while phase 2 determined the dose-dependent efficacy. For both phases, drug treatment began 24 hours after surgically induced venous thrombosis and continued for four days.Phase 1 animals (n = 24) receiving low-dose (LD; 1 mg/kg oral gavage) PAI-1 inhibitor demonstrated a 52% decrease in thrombus weight (TW) versus controls (p < 0.05) with significant reductions in active plasma PAI-1, while the high-dose (HD; 10 mg/kg oral gavage) group demonstrated a 23% reduction in TW versus controls.Animals treated subcutaneously with LOV (3 mg/kg) showed a 39% decrease in TW versus controls (p < 0.05). Coagulation tests (aPTT andTCT) were significantly different in LOV compared to PAI-1 inhibitor groups. PAI-039 treatment was also associated with significantly increased return of inferior vena cava blood flow four days post-thrombosis versus controls (p < 0.05). In phase 2 (n = 30),TW was reduced from the 0.5 mg/kg to 5 mg/ kg experimental groups,with the 10 mg/kg group demonstrating a paradoxical increase. The 5 mg/kg group showed statistically significant decreases inTW versus controls after four treatment days (p < 0.05).This is the first study to demonstrate dose related effects of PAI-039 on increasing thrombus resolution and inferior vena cava blood flow without adverse effects on anti-coagulation in a rat stenosis model of venous thrombosis.

You may also be interested in...

1.
Martin J. O’Donnell 1, Simon McRae 1, Susan R. Kahn 2, Jim A. Julian 1, Clive Kearon 1, Betsy MacKinnon 1, Debbie Magier 3, Carla Strulovich2,Theresa Lyons 1, Sandra Robinson 3, Jack Hirsh 1, Jeffrey S. Ginsberg1,2

Thromb Haemost 2008 99 3: 623-629

http://dx.doi.org/10.1160/TH07-09-0546

2.
Peter K. Henke 1 , Manu R. Varma 1 , K. Barry Deatrick1 , Nicholas A. Dewyer 1 , Erin M. Lynch1 , Andrea J. Moore1 , Derek A. Dubay 2 , Pasu Sukheepod1 , Charles G. Pearce1 , Gilbert R.Upchurch, Jr. 1 , Steven L. Kunkel3 , Michael G. Franz 2 , Thomas W

Thromb Haemost 2006 95 2: 272-281

http://dx.doi.org/10.1160/TH05-02-0099

3.

Online Supplementary Material

See also Saha, Smith

N. A. Dewyer (1), O. M. El-Sayed (1), C. E. Luke (1), M. Elfline (1), N. Kittan (2), R. Allen (2), A. Laser (1), C. Oostra (3), A. Comerota (3), C. Hogaboam (2), S. L. Kunkel (2), P. K. Henke (1)

Thromb Haemost 2015 114 5: 1028-1037

http://dx.doi.org/10.1160/TH14-12-1031